Parnax Lab

Which are the latest news on Parnax Lab?

How big is Parnax Lab?

As of 10th June, Parnax Lab Ltd has a market capitalization of 153.00 Cr, with net sales of 248.55 Cr and a net profit of 11.79 Cr reported in the latest four quarters. The balance sheet for March 2025 shows shareholder's funds of 83.10 Cr and total assets of 189.82 Cr.

As of 10th June, Parnax Lab Ltd has a market capitalization of 153.00 Cr, which classifies it as a Micro Cap company.<BR><BR>In the latest four quarters, Parnax Lab reported net sales of 248.55 Cr and a net profit of 11.79 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing shareholder's funds of 83.10 Cr and total assets of 189.82 Cr.

Why is Parnax Lab Ltd falling/rising?

As of 10-Jun, Parnax Lab Ltd's stock price is at 126.50, down 4.89% after a trend reversal. The stock is underperforming its sector and trading below all key moving averages, indicating a bearish trend.

As of 10-Jun, Parnax Lab Ltd's stock price is falling, currently at 126.50, which reflects a decrease of 6.5 or 4.89%. This decline follows a trend reversal after two consecutive days of gains. The stock has underperformed its sector by 4.37% today and has touched an intraday low of Rs 125.2, marking a drop of 5.86%. <BR><BR>Additionally, Parnax Lab is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Investor participation has also decreased, with delivery volume falling by 11.77% compared to the 5-day average. These factors collectively contribute to the stock's current downward movement.

What does Parnax Lab do?

Parnax Lab Ltd manufactures and exports pharmaceutical formulations, operating as a Micro Cap company in the Pharmaceuticals & Biotechnology industry. As of March 2026, it reported net sales of 70 Cr and a net profit of 2 Cr, with a market cap of INR 153 Cr.

Overview: <BR>Parnax Lab Ltd is engaged in the manufacturing and export of pharmaceutical formulations and operates within the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History: <BR>Parnax Lab Ltd was incorporated in August 1982 and was formerly known as Krishna Deep Trade & Investment Ltd until it changed its name on July 19, 2012. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 70 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 2 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 153 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 11.00 <BR>Industry P/E: 21 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.87 <BR>Return on Equity: 13.57% <BR>Price to Book: 1.61 <BR><BR>Contact Details: <BR>Address: Gala 114 Bldg No 8, Jogani Ind Complex Chunabhatti Mumbai Maharashtra : 400022 <BR>Phone: 91-022-6825 2525 <BR>Email: info@naxparlab.com <BR>Website: http://www.naxparlab.com

Should I buy, sell or hold Parnax Lab Ltd?

Are Parnax Lab Ltd latest results good or bad?

Parnax Lab Ltd's latest results show strong revenue growth of 41.99% year-on-year, reaching ₹69.63 crores, but a significant decline in net profit by 25.34% raises concerns about profitability and operational challenges, placing the company in the "SELL" territory. Investors should be cautious due to these mixed signals.

Parnax Lab Ltd's latest results present a mixed picture, highlighting both strengths and significant concerns. On the positive side, the company achieved a record revenue of ₹69.63 crores in Q4 FY26, reflecting a strong year-on-year growth of 41.99% and a sequential increase of 10.63%. This indicates robust sales performance and a consistent growth trajectory.<BR><BR>However, the net profit has declined sharply to ₹2.18 crores, down 19.56% quarter-on-quarter and 25.34% year-on-year. This decline is particularly concerning given the strong revenue growth, suggesting that the company's profitability is under pressure. The operating margin has also contracted to 7.02%, the lowest in eight quarters, indicating rising costs that are not being offset by revenue gains.<BR><BR>Moreover, a significant portion of the profit before tax (61.61%) is coming from other income, raising questions about the sustainability and quality of earnings. The company's Mojo Score of 44/100 places it in the "SELL" territory, reflecting concerns about its financial health and fundamental strength.<BR><BR>In summary, while Parnax Lab has demonstrated impressive revenue growth, the declining profitability and margin pressures indicate that the latest results are more concerning than positive. Investors should approach the stock with caution, particularly given the current operational challenges.

When is the next results date for Parnax Lab Ltd?

The next results date for Parnax Lab Ltd is 28 May 2026.

The next results date for Parnax Lab Ltd is scheduled for 28 May 2026.

How has been the historical performance of Parnax Lab?

Parnax Lab has shown steady growth in net sales and profitability, with net sales reaching 187.74 Cr in March 2025, up from 163.03 Cr in March 2022. Key financial metrics, including profit after tax and earnings per share, have also improved, reflecting a positive trend in overall performance.

Answer:<BR>The historical performance of Parnax Lab shows a steady growth in net sales and profitability over the years, culminating in the latest figures for March 2025.<BR><BR>Breakdown:<BR>Parnax Lab's net sales increased slightly to 187.74 Cr in March 2025 from 188.71 Cr in March 2024, showing a growth trend from 167.61 Cr in March 2023 and 163.03 Cr in March 2022. The total operating income mirrored this trend, reaching 187.74 Cr in March 2025. The total expenditure, excluding depreciation, decreased to 160.97 Cr in March 2025 from 165.17 Cr in March 2024, contributing to an operating profit (PBDIT) of 28.45 Cr, up from 24.36 Cr the previous year. Profit before tax also rose to 15.67 Cr in March 2025, compared to 12.05 Cr in March 2024, while profit after tax reached 11.54 Cr, an increase from 9.62 Cr. The earnings per share improved to 10.03 in March 2025 from 8.36 in March 2024. On the balance sheet, total assets stood at 189.82 Cr in March 2025, slightly down from 190.26 Cr in March 2024, with total liabilities also decreasing to 189.82 Cr from 190.26 Cr. The company maintained a book value per share of 72.35 in March 2025, up from 62.32 in March 2024. Cash flow from operating activities significantly improved to 32.00 Cr in March 2025 from 15.00 Cr in March 2024, indicating a positive cash flow trend.

Is Parnax Lab overvalued or undervalued?

As of November 10, 2025, Parnax Lab is considered an attractive investment opportunity due to its undervalued status with a PE ratio of 13.34 and strong financial ratios, despite a year-to-date stock decline of 25.27%.

As of 10 November 2025, Parnax Lab's valuation grade has moved from fair to attractive, indicating a more favorable assessment of its stock. The company is currently considered undervalued, supported by a PE ratio of 13.34, an EV to EBITDA of 8.24, and a ROE of 13.86%. In comparison to its peers, Parnax Lab's valuation stands out against Elitecon International, which is deemed very expensive with a PE ratio of 359.8, and PTC India, which is classified as very attractive with a PE ratio of 7.89.<BR><BR>Despite recent stock performance showing a decline of 25.27% year-to-date compared to a 6.91% gain in the Sensex, Parnax Lab's strong financial ratios and improved valuation grade suggest that it may present a compelling investment opportunity. The company's solid fundamentals, including a PEG ratio of 2.54, further reinforce the notion that it is undervalued relative to its peers in the pharmaceuticals and biotechnology industry.

What is the technical trend for Parnax Lab?

As of May 27, 2025, Parnax Lab's technical trend is mildly bearish, influenced by daily moving averages and mixed signals from MACD and Bollinger Bands, despite some bullish indicators on the weekly chart.

As of 27 May 2025, the technical trend for Parnax Lab has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands show a bullish stance on the weekly chart but are mildly bearish on the monthly chart. Moving averages are mildly bearish on the daily timeframe. The KST is mildly bullish weekly but mildly bearish monthly, and Dow Theory supports a mildly bullish outlook on both weekly and monthly timeframes. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the mixed signals from the MACD and Bollinger Bands.

Who are the top shareholders of the Parnax Lab?

The top shareholders of Parnax Lab include promoters, with Binoy Baiju Shah holding the largest individual stake at 11.92%. Individual investors own 24.73% of the shares, while the highest public shareholder is Suman Gupta at 1.62; there are no mutual funds or foreign institutional investors involved.

The top shareholders of Parnax Lab primarily consist of promoters, with Binoy Baiju Shah holding the highest individual stake at 11.92%. Additionally, individual investors collectively hold 24.73% of the shares. Notably, there are no mutual funds or foreign institutional investors (FIIs) currently holding shares in the company. The highest public shareholder is Suman Gupta, who holds 1.62%.

Who are in the management team of Parnax Lab?

As of March 2022, the management team of Parnax Lab includes Prakash M Shah (CEO), Baiju M Shah (CFO), and several directors, including Vindyak B Desai, T V Anantharaman, and Yogesh Varia, along with Company Secretary Preet Vijay Kukreja. Each member contributes to the company's governance and operations.

As of March 2022, the management team of Parnax Lab includes the following individuals:<BR><BR>1. Vindyak B Desai - Independent Director<BR>2. Prakash M Shah - Director & Chief Executive Officer<BR>3. Baiju M Shah - Managing Director & Chief Financial Officer<BR>4. Ami M Shah - Director<BR>5. T V Anantharaman - Independent Director<BR>6. Yogesh Varia - Independent Director<BR>7. Preet Vijay Kukreja - Company Secretary & Compliance Officer<BR><BR>Each member plays a distinct role within the company's governance and operational structure.

Has Parnax Lab declared dividend?

No Dividend History Available

Who are the peers of the Parnax Lab?

Parnax Lab's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. In terms of management risk, growth, and capital structure, Parnax Lab ranks below average compared to its peers, with a 1-year return of 11.79%.

Peers: The peers of Parnax Lab are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Source Natural, Bharat Immunolog, Samrat Pharma, Mercury Labs, and Ajooni Biotech.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Samrat Pharma, while Good management risk is found at Divi's Lab., Source Natural, and the rest. Below Average management risk is noted for Parnax Lab, Bharat Immunolog, and Ajooni Biotech. In terms of Growth, Excellent growth is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good growth is noted for Parnax Lab. Below Average growth is present at Divi's Lab., Torrent Pharma, Source Natural, Bharat Immunolog, and Ajooni Biotech. Excellent capital structure is exhibited by Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Mercury Labs, while Good capital structure is found at Torrent Pharma and Samrat Pharma, and Below Average capital structure is noted for Parnax Lab and Bharat Immunolog.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while Bharat Immunolog has the lowest at -9.56%. Parnax Lab's own 1-year return is 11.79%, which is higher than Bharat Immunolog's but lower than Divi's Lab.'s. Additionally, the peers with negative six-month returns include Parnax Lab, Source Natural, Mercury Labs, and Bharat Immunolog.